<DOC>
	<DOCNO>NCT01871558</DOCNO>
	<brief_summary>To compare therapeutic strategy combine vildagliptin+metformin + Basal Insulin versus SU+metformin + Basal Insulin incidence hypoglycemic event 24 week .</brief_summary>
	<brief_title>Vildagliptin/Metformin T2DM Patients Starting Basal Insulin</brief_title>
	<detailed_description>This study , conduct T2DM patient fail dual therapy metformin/SU decision start basal insulin take , compare vildagliptin+metformin versus previously use SU+met combination ( regimen keep unchanged ) association basal insulin , up-titrated per usual algorithm primarily base FPG obtain similar improvement glycemic control arm , incidence hypoglycemic episodes 24 week .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>T2DM patient inadequately control metformin+ SU combination therapy max tolerate dos decision start basal insulin take stable metformin+ SU combination therapy least 12 week prior randomization glycemic target HbA1c &lt; = 7 % HbA1c inclusion &gt; 7 % &lt; =9 % Patients willing able start basal insulin perform appropriate self monitoring blood glucose ( SMBG ) contraindication either SUs , metformin insulin history hypersensitivity vildagliptin acute chronic disease interfere efficacy/safety result trial put patient risk Other protocol define inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>type 2 diabetes</keyword>
	<keyword>basal insulin</keyword>
	<keyword>vildagliptin</keyword>
</DOC>